@article{fe103d1e268441d4b406d551a5190a9e,
title = "A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus",
abstract = "Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachment glycoprotein ectodomain, a subunit vaccine formulation for use in people is now in a Phase I clinical trial. We report that a single dose vaccination regimen of this human vaccine formulation protects against otherwise lethal challenges of either Hendra or Nipah virus in a nonhuman primate model. The protection against the Nipah Bangladesh strain begins as soon as 7 days post immunization with low dose of 0.1 mg protein subunit. Our data suggest this human vaccine could be utilized as efficient emergency vaccine to disrupt potential spreading of Nipah disease in an outbreak setting.",
author = "Geisbert, {Thomas W.} and Kathryn Bobb and Viktoriya Borisevich and Geisbert, {Joan B.} and Agans, {Krystle N.} and Cross, {Robert W.} and Prasad, {Abhishek N.} and Fenton, {Karla A.} and Hao Yu and Fouts, {Timothy R.} and Broder, {Christopher C.} and Dimitrov, {Antony S.}",
note = "Funding Information: We thank Profectus BioSciences, Inc. team: John Eldridge, Terry Higgins, Marc Trembley, Tracy Chen, and Jeffrey Meshulam for continuous operational and quality control support; UTMB Animal Resource Center for husbandry support of laboratory animals, Daniel Deer and Drs. Kevin Melody and Chad Mire for assistance with the animal studies, Natalie Dobias for expert histology and immunohistochemistry support; and Dr. Linfa Wang for the anti-N antibody gift to Dr. Broder. We are also thankful to our CRO teams at Charles River Laboratories for manufacturing and testing the HeV-sG master cell bank and at Catalent Pharma for developing the vaccine GMP manufacturing process and producing the tox lot vaccine used in the reported studies. The work was financially supported by NIAID, NIH, through grant award R01AI098760 to Drs. T.R. Fouts and A.S. Dimitrov while at Profectus BioSciences, Inc. and by the DHHS, NIH grant UC7AI094660 for BSL-4 operations support of the Galveston National Laboratory. Publisher Copyright: {\textcopyright} 2021, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.",
year = "2021",
month = dec,
doi = "10.1038/s41541-021-00284-w",
language = "English (US)",
volume = "6",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",
}